Future Perspectives in the Treatment of Polycythemia Vera
John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.
Ruxolitinib in the Treatment of PV
Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.
Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV
Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.
Treatment Approaches for High-Risk Patients With PV
Drs Joe Scandura and John Mascarenhas discuss their treatment approaches for high-risk patients with polycythemia vera.
Key Trials in the Treatment of PV
Experts review critical trial data in the treatment of patients with polycythemia vera.
Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV
Joe Scandura, MD, PhD, summarizes the toxicity profile of interferon therapy in patients with polycythemia vera.
Managing Toxicities of Hydroxyurea in Patients With PV
Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.
Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV
Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.
Reducing Risk of Thrombosis in Patients With PV
Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.
Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis
John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.
Importance of Bone Marrow Biopsy For Diagnosis of PV
Experts explain the critical importance of obtaining bone marrow biopsies for accurately diagnosing polycythemia vera.
Typical Presentation of a Patient With PV
John Mascarenhas, MD, and Joe Scandura, MD, PhD, detail the typical presentation of a patient with polycythemia vera in their clinical practices.
Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis
John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.
Reducing Risk of Disease Progression in Patients With PV
Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.
Risk Assessment in Patients With Polycythemia Vera (PV)
Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.
Dr Mascarenhas on the Initial Efficacy of Navtemadlin Plus Ruxolitinib in Myelofibrosis
John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.
Dr Mascarenhas on Ongoing Research in Myelofibrosis
John Mascarenhas, MD, discusses ongoing trials and research in myelofibrosis.
Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis
John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
Dr. Mascarenhas on the Benefit of Fedratinib in Myelofibrosis
John Mascarenhas, MD, discusses the benefit of fedratinib for patients with myelofibrosis.
Dr. Mascarenhas on the Role of Pacritinib in Myelofibrosis
John Mascarenhas, MD, discusses the role of pacritinib in patients with myelofibrosis.
Myeloproliferative Neoplasm Management: Future Directions in Care
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms
Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.
An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation
A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.
Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.
What is the Role of Transplant in Managing Patients With Myelofibrosis?
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies
Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.
Myelofibrosis: Nuancing the Potential of Disease Modification
A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.
Therapy in Myelofibrosis: Pacritinib
Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.
Novel Therapy in Myelofibrosis: Momelotinib
Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.
Role of Symptom Burden in Thrombocythemia and Polycythemia Vera
Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
2 Clarke Drive Cranbury, NJ 08512